

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60432	SERIAL NO. 10/567,803
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Coles, et al.	
		FILING DATE March 31, 2008	GROUP 1615

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/D.A./	Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32.
EXAMINER	DATE CONSIDERED
/Danah Al-awadi/	08/16/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.